Common Lameness in Dressage Horses, Risk Factors and Treatment Options

Dr Danica Olenick, DVM Swiftsure Equine Veterinary Services October 17, 2017

Lameness Prevalence in Dressage

- O Research Questionnaire of 2500 Dressage horses in the UK
 - Involved 80% non-eine, 11% eine and 9% unknown ieve
 33% had been lame at rame point in their career
 - 24% had been lame within the previous 2 years
 - O Highest proportion of lame horses were at the elite lev
 - 50% Grand Prix horses
 - 0 33% Intermediare horses
 - Average time off of riding was 3 months, and away from competition w
 - Elite horses were off for longer than non-elite horses
 - Mummietal 2010. "Identification of title fact and a lamonar in

Lameness Locations

- Over 31% of reported lameness originated in the hoof
- 25% involved the bo
- O 13% involved the suspensory ligamen
- 11% involved the hocks
- O Most common was forelimb lameness
- 23% left front, 20% right front, 12% bilater
- 12% left hind, 11% right hind, 6% bilateral
- 3% had 3 limbs affected and 1 % had all four limbs affected

General Concepts

- O Multiple injuries often present simultaneously
- Horses after their agit to compensate for one injury. leading to additional stress elsewhorder
- The horse's back is commonly the site of compensatory stress and pain
- Riders may become aware of back pain (secondary) before a lameness (primary)
- - Larger heavier horses are more likely to injure limbs as the longer limbs have to handle more pressure and power

The Biomechanics

- O Training/Lower levels emphasize balance and freedom of movement O Younger horses, with immature musculoskeletal systems
- O Intermediate levels emphasize more lateral movements
- Changes in astribution of weight medic-la
- Advanced levels require maximum collection, impulsion and suspension
- Older horses, more time for wear and tear on joints
- o mosi siressis placed on the hind doarters, back and pervis

Common Lameness in Dressage Horses

OA of Coffin Joints (Low Ringbone)

- O Common lameness in all performance horses
- O Clinical signs (C/S) are a shortened stride Most commonly bilateral in FRONT distal joints
- O Weight of the horse, hoof conformation, medial and lateral imbalances
- Diagnosed (DX) by nerve blocks and x-rays
- MRI very useful to diagnose other conditions of the hoof
- O Treatment (TX) intra-articular (IA) injections, IRAP, corrective shoeing

Back Pain

- O C/S: Poor performance, unwillingness to perform certain movements, lack of impulsion, stiffness

Proximal Suspensory Desmitis (PSD)

- Bildreal cases are difficult to diagnose as no overt lameness, just reduced performance, stiffness or resistance to movements, difficulties with provettes and flying changes
- Common Cause: Increased loading in collected trot, platfe and passage movements when distaljoints are in increased extension and hock joints are in increased flexion
- DX: nerve blocks, U/S, MRI
- TX: Rest & Rehabilitation, ESWT, PRP, Stem cells, Surgery
- Fair prognosis
 - Conformation & duration of injury are major factor affecting prognosis

Forelimb PSD

- Common Cause: Extravagant movement with insufficient muscle strength and coordination to prevent hyperextension of carpus and metacarpal phalangeal joints

OA of Distal Hock Joints (Bone Spavin)

- O Most commonly bilateral in Distal Intertarsal (DIT) joints and Tarsometatarsal (TMT) joints
- C/S: Reduced expression at trot, difficulties in canter, collected gaits, difficulties with rhythm in piaffe and passage, toe dragging, shortened stride
- Common Cause: Circling and other specific movements, increased loading and compression of tarsal joints
- O DX: nerve blocks, x-rays
- O TX: IA injections, IRAP, other therapies
- Good to excellent prognosis



Risk factors

- O Height : 15% increase risk in horses above 17.0 HH (170cm) than horses below 16.0 HH (163cm)

- O Horses with respiratory disease are more than 4 times more likely to be lame

Exercise regimes

- O Walk warmup slight increase in lameness
- O Lunging slight decrease in lameness
- May be the horse has improved coordination and adaptation of the musculoskeletal system
- O Horses that are jumped or turned out on pasture for prolonged periods are less likely to be
- lame
- O Improves flexibility, core muscle strength, fitness O May also be the horse has improved coordination and adaptation of the musculoskeletal system*

- Arena surfaces
- Surfaces that were likely to become deeper when wet
- Waxed sand or sand with rubber less likely than
- sand alone, sand with pvc, woodchips or grass
- O Indoor arenas more likely to cause lameness
- Smaller Size
- Sand arena more likely to cause lameness, but then become less likely the more days per week the horse is ridden in it

Take Home Messages

- O If a horse is only worked on one type of surface, they are more likely to become injured when they are worked on a different surface

- Training needs to focus on strength and stamina just as much as skill
- O Horses should be ridden in large, well maintained rings that are not prone to becoming deep or boggy when we



IRAP Therapy

- Derived from the horse's own blood

O How it works:

- O These proteins cause carillage degeneration and potentiate further inflammation, inflammatory protein production and joint damage (degenerative cycle)

IRAP Production

• How it's made:

- Doses are frozen and stored

• Treatment Protocol:

IRAP Benefits/Drawbacks

- Will not trigger steroid-induced laminitis

O Drawbacks:

• Same risk of joint infection

PRP Therapy

- PRP = Platelet Rich Plasma
- O Used for the treatment of injured tendons and ligaments
- Derived from the horse's blood

• How it works:

PRP Production

• Treatment Protocol:

- PRP is used immediately (not frozen and stored)
 PRP is injected with ultrasound guidance into the core lesion of a tendon or ligament

PRP Considerations

- Not all PRP have the same concentration of platelets
- Platelets need to be activated to release their growth factors either before or during injection otherwise there will be no beneficial effects

O Same risk of infection

- Has to be collected and administered in-hospital, or same location as processing (is not done on farm)

Pro-Stride • Beneficial where inflammation is present AND tissue healing is required Blood is collected and processed ON-FARM within 20 min • Appropriate for metabolically-challenged horses

Stem Cells

- Mesenchymal Stem Cells (MSC) are used in healing a joints, bone and tissue
- MSC integrate into the tissue themselves differentiating into specialized tissue types leading to regeneration of the tissue
- O MSC also stimulate the healing process thu release of growth factors and anti-inflammatary proteins, recruitment of blood vessels and stimulation of local cells to regenerate



Stem Cells con't

- MSC are derived from bone marrow, fat cells, umbilical tissue and umbilical blood
- In horses, MSC are typically collected from the bone marrow in the sternum
- O Marrow harvested under standing sedation and local block
- Stem cells are cultured in a lab
- Treatment typically involves 2 or 3 repeated injections, a month apa
- Not (easily) available in Canada
 Most expensive treatment

Noltrex & Arthramid

- Polyacrylamide hydrogel
- Designed for the treatment of OA
- Synthetic, inert, biocompatible, non-soluble IA therapy
- Designed to mimic the visco-elastic and lubricating properties of synovial fluid
- Longer-acting compared to traditional Steroid/HA joint injection

Osphos & Tildren

- Bisphosphonates labelled for use in Navicular Syndrome
- Inhibit bone resorption by inducing the cell death of osteoclast (bone-eating) c
- Effect is the reduction of bone-related pain
- O Has been used off-label for other types of bone pain
- Osphos is administered intra-muscularly
- O Tildren is administered intra-venously
- O Osphos shown to reduce lameness by one grade in 67% of horses within 1 month and 75% of horses within 2 months
- Both carry risks of colic and kidney damage

Legend

- Hyaluronic Acid (HA)
- Used for the frediment of Osteodrinnis (OA)
- Reduces the production drid release of initial
- Simulates the production of the joint's own HA
- Administered intra-venously (IV) or intra-articularly (IA)
- Clinical improvement in 90% of horses after IV and 96% after IA administration

Cartrophen Equine Forte

- Pentosan Polysulfate
- Prevention and Treatment of OA
- Improves cartilage health
- Stimulates the joints to produce HA
- Reduces production and release of inflammatory protein
- Administered intra-muscularly (IM)
- Clinical improvement in 60% of cases
- Not currently available in Canada (but Cartrophen Vet for dogs is available)